Vera Therapeutics (VERA)
(Delayed Data from NSDQ)
$38.69 USD
-1.26 (-3.15%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $39.20 +0.51 (1.32%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.69 USD
-1.26 (-3.15%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $39.20 +0.51 (1.32%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum D VGM
Zacks News
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
by Zacks Equity Research
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Vera Therapeutics, Inc. (VERA) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
by Zacks Equity Research
Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround
by Zacks Equity Research
Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock
by Zacks Equity Research
Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Buy Vera Therapeutics (VERA) Ahead of Earnings?
by Zacks Equity Research
Vera Therapeutics (VERA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax
by Zacks Equity Research
Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.
Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More
by Zacks Equity Research
Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.
VERA Dips Despite Positive Data From IgA Nephropathy Study
by Zacks Equity Research
VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
Wall Street Analysts Think Vera Therapeutics, Inc. (VERA) Could Surge 64%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Vera Therapeutics, Inc. (VERA) points to a 63.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 76% Upside in Vera Therapeutics, Inc. (VERA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 76.2% upside potential for Vera Therapeutics, Inc. (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Vera Therapeutics, Inc. (VERA) Climb 79% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 78.8% upside potential for Vera Therapeutics, Inc. (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vera Therapeutics (VERA) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Vera Therapeutics (VERA) has been struggling lately, but the selling pressure may be coming to an end soon.